Quanterix Corporation · NASDAQ:QTRX
Quanterix — Technical Presentation (October 2015)
34 slides from Quanterix's technical presentation, Oct 29, 2015

Slide 1: Simoa 2.0: Single molecule array Technology and Applications
Simoa 2.0: Single molecule array Technology and Applications Dr. David C. Duffy Chief Technology Officer, Quanterix Corporation

Slide 2

Slide 3: The Opportunity for Simoa HD-1 Analyzer
The Opportunity for Simoa HD-1 Analyzer Serum Total Number of 171 FDA Approved Tests3 Clinical Chemistry Concentration Serum Proteins 1 x 10−3 M to 3251 1 x 10-12 M ELISA How many proteins Are below 1 x 10-12 M? Potential is Large: Simoa • Human Proteome = Opportunity 20,243 genes1 • Secreted Protei

Slide 4: Simoa Provides a Digital Advantage
Simoa Provides a Digital Advantage Traditional (Analog) 0 pM 10 pM • Reaction volume = 100 ×10−6 L • Diffusion = dilution = low sensitivity • Millions of molecules needed to reach detection limit SiMoA (Digital) 0 aM 3.5 aM 350 aM 3.5 fM • Reaction volume = 50 ×10−15 L (2 billion times smaller) • Di

Slide 5: Simoa enables Single Molecule Diagnostics
Simoa enables Single Molecule Diagnostics

Slide 6: Counting Single Protein Molecules in Blood using Simoa
Counting Single Protein Molecules in Blood using Simoa 10 mm C 10 µm Rissin et al., Nat. Biotechnol. 2010, 28, 595-599 Kan et al., Lab Chip 2012, 12, 977-985

Slide 7: Multiplexed Single Molecule Immunoassays
Multiplexed Single Molecule Immunoassays I. Formation of multiplex immunocomplex II. Load, seal and image of multiplex beads Rissin et al. Lab Chip 2013, 13, 2902

Slide 8: Simoa uses digital counting with Poisson statistics and intensity
Simoa uses digital counting with Poisson statistics and intensity to determine average number of enzymes per bead (“AEB”) AEB ~ 0.1 AEB ~ 0.6 AEB ~ 3.0 Rissin et al., Anal.Chem. 2011, 83, 2279-2285

Slide 9: Intensity measurements extend dynamic range: Analog + Digital
Intensity measurements extend dynamic range: Analog + Digital Digital-to-analog threshold • Determine average intensity produced by the beads on an array (Ībead) • Determine average intensity produced by a single enzyme (Īsingle) • Analog AEB is ratio of these two numbers • Combined digital and anal

Slide 10: High sensitivity to enzyme label enabled subfemtomolar detection
High sensitivity to enzyme label lowered backgrounds and enabled subfemtomolar detection of proteins using Simoa Rissin et al., Nat. Biotechnol. 2010, 28, 595-599

Slide 11: Simoa quantifies proteins in the fg/mL range
Simoa quantifies proteins in the fg/mL range Conventional Simoa LoD Sensitivity Fold Protein immunoassay LoD Comparator (pg/mL) Increase (pg/mL) Ab42 0.034 50 Innotest 1471x Tau 0.017 60 Innotest 3500x IL-6 0.002 0.7 R&D Systems 350x TNF-a 0.014 0.60 R&D Systems 43x C-peptide 0.013 30 ALPCO 2300x IL

Slide 12: Simoa HD-1 Analyzer
Simoa HD-1 Analyzer • Unprecedented sensitivity • Full automation • Precision • Wide dynamic range • Easy & cost-effective implementation • Multiplexing capability with small sample volumes • Homebrew capabilities • ~400 samples per shift • Available for RUO • bioMérieux to seek regulatory approval

Slide 13: HD-1 Analyzer: User Workflow Step 1: Define assays
Simoa HD-1 Analyzer: User Workflow Step 1: Define assays on Touchscreen GUI

Slide 14: HD-1 Analyzer: User Workflow Step 2: Load Reagents
Simoa HD-1 Analyzer: User Workflow Step 2: Load Reagents • Multiplexed Beads • Detection antibodies • Enzyme conjugate

Slide 15: HD-1 Analyzer: User Workflow Step 3: Load Samples
Simoa HD-1 Analyzer: User Workflow Step 3: Load Samples • Up to 4 96-well plates OR • Up to 96 primary tubes

Slide 16: HD-1 Analyzer: User Workflow Step 4: Load Consumables
Simoa HD-1 Analyzer: User Workflow Step 4: Load Consumables • Up to 6 boxes of 96 tips • Up to 500 cuvettes • Up to 2 stacks of 16 Simoa discs

Slide 17: HD-1 Analyzer: User Workflow Step 5: Check Liquids and Waste
Simoa HD-1 Analyzer: User Workflow Step 5: Check Liquids and Waste • Solid & Liquid waste • System fluids

Slide 18: HD-1 Analyzer: User Workflow Step 6: Press Start
Simoa HD-1 Analyzer: User Workflow Step 6: Press Start and automation does the rest

Slide 19: HD-1 Analyzer: User Workflow Step 7: Review Data
Simoa HD-1 Analyzer: User Workflow Step 7: Review Data!

Slide 20: Simoa HD-1: LoD comparison
Lower normal plasma or clinical* ranges (median) Simoa HD-1: LoD comparison1 Leading vendor of ELISA LoD (2.5 SD) Quanterix LoD (2.5 SD) PSA *Range depicted: post radical prostatectomy patients Troponin Ab40 Ab42 Tau IL-2 IL-6 IL-8 Assay IL-10 IL-13 TNF-a IL-15 IL-17A GM-CSF IFN-a C-peptide *Range d

Slide 21: HD-1: Precision
Simoa HD-1: Precision 10-run precision study per CLSI; Simoa p24 assay LoD of conventional p24 immunoassays p24, ng/L Run Unpublished data

Slide 22: Simoa Addresses Many Opportunities for High Sensitivity Diagnostics
Simoa Addresses Many Opportunities That Exist for High Sensitivity Clinical and Companion Diagnostics Brain Blood Infectious Disease Endothelial Cells Simoa is first IA to be as Cardiovascular Disease sensitive to virus as PCR Neurodegenerative Disease Simoa is world’s most sensitive troponin test S

Slide 23: Recent Application Example: Cardiology
Recent Application Example: Cardiology Cardiac Damage marker (Troponin I) (with Brigham & Women’s Hospital) • Achieved 600-fold greater sensitivity than benchmark ultrasensitive Siemens Ultra cTnI assay (LoD: 0.01 ng/L vs. 6 ng/mL), a limit of quantification of 0.08 ng/L, a total CV of 10% at 2.0 ng

Slide 24: Recent Application Example: Microbiology
Recent Application Example: Microbiology C. Difficile (Toxins A and B) (with Profs. Nira Pollock and Ciaran Kelly, BIDMC) • Developed Simoa assays for Toxins A & B from C. diff. in stool with LODs of 0.45 and 1.5 pg/mL compared to ~1 ng/mL for current IVD tests • Measured both toxins using Simoa in

Slide 25: Recent Application Example: Fully Automated 6-plex Cytokine Detection
Recent Application Example: Fully Automated 6-plex Cytokine Detection Cytokine concentrations of CD patients before Cytokine concentrations in serum and after treatment with anti-TNF-a drugs of Type I Diabetics Rivnak et al., J. Immunol. Methods 2015, 424, 20-27.

Slide 26: Application Example: Digitized Homebrew: ELISA
Application Example: Digitized Homebrew: ELISA Protein Resorufin b-D- galactopyranoside Resorufin

Slide 27: Simoa Accelerator Laboratory Capabilities
Simoa Accelerator Laboratory Capabilities • Work directly with Quanterix scientists or send reagents/samples • Develop ultrasensitive prototype assays using homebrew kit on HD-1 analyzer. Further optimization and validation of prototype assays available • Testing capabilities from a single plate of

Slide 28: Shipping now! Available to all existing customers as free upgrade
• Shipping now! • Available to all existing customers as free upgrade

Slide 29: What is Simoa 2.0?
What is Simoa 2.0? • Simoa 2.0 is Quanterix’ next generation Simoa platform and includes numerous improvements to assay performance, hardware and software refinements, as well as overall instrument usability • Significant improvements in overall instrument reliability & stability via hardware and so

Slide 30: Simoa 2.0: Highlights
Simoa 2.0: Highlights Improvement Features Reliability >20 hardware improvements, including • Washer/Incubator Module Optimization • Cuvette Loader Module improvements 65 software and firmware bug fixes Robustness of precision New 2.0 assay protocol Software Version 1.5 48 new, customer-driven featu

Slide 31: Simoa HD-1 supports CFR 21 Part 11 compliance
Simoa HD-1 supports CFR 21 Part 11 compliance • User access right management system • Access control to every part of application • Multi-layer hierarchy of user groups • Automatic export of results to LIMS • Strong password policy • Automatic logout • Audit trails • Desktop Shield • Limits access t

Slide 32: The Simoa 2.0 Team!
The Simoa 2.0 Team! Quanterix

Slide 33: Thank You!
Thank You! Email: dduffy@quanterix.com

Slide 34: Simoa 2.0 Assay Protocol
Simoa 2.0 Assay Protocol Quanterix has developed an enhanced assay protocol (Simoa 2.0 Assay Protocol) that provides optimal assay precision, improved CVs and overall assay robustness. Reduced site-to-site variability and greatly improved precision. Elimination of low outliers that negatively impact
Source: Internet Archive copy of quanterix.com
More decks from Quanterix Corporation
Q3 2026 Earnings Presentation21 slides · Nov 9, 2026
Q2 2026 Earnings Presentation21 slides · Aug 10, 2026
Q1 2026 Earnings Presentation17 slides · May 6, 2026
FY2025 Earnings Presentation14 slides · Mar 2, 2026
Q3 2025 Earnings Presentation11 slides · Nov 10, 2025
Q2 2025 Earnings Presentation12 slides · Aug 7, 2025